Inferior Long-Term Outcomes for Kidney Transplant Recipients With an Immunologically Mediated Primary Renal Disease

被引:1
作者
Favi, Evaldo [1 ]
Rodrigues Pedroso, Ose Alberto [2 ]
Salerno, Maria Paola [3 ]
Spagnoletti, Gionata [3 ]
Romagnoli, Jacopo [3 ]
Citterio, Franco [3 ]
机构
[1] Osped Maggiore Policlin, Fdn IRCCS Ca Granda, Renal Transplantat Unit, Milan, Italy
[2] Univ Fed Rio Grande do Sul, Nephrol Dept, Hosp Clin Porto Alegre, Porto Alegre, RS, Brazil
[3] Fdn Policlin Univ A Gemelli, Renal Transplantat Unit, Rome, Italy
关键词
Glomerulonephritis; Graft survival; Recurrence; Renal function; Renal transplant; SEGMENTAL GLOMERULOSCLEROSIS; RECURRENT GLOMERULONEPHRITIS; RISK;
D O I
10.6002/ect.2017.0025
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Objectives: Recurrent glomerulonephritis can negatively affect kidney allograft survival. However, how primary renal disease affects transplant outcomes in the new era of immunosuppression remains unclear. Materials and Methods: We categorized 426 kidney transplant recipients (performed from 1996 to 2007) into 4 disease groups: (1) 99 recipients with biopsyproven immunologically mediated kidney disease, (2) 40 recipients with urologic disease, (3) 67 recipients with polycystic kidney disease, and (4) 220 recipients with other causes of terminal renal failure/ uncertain kidney disease. Long-term transplant outcomes were compared between groups at 1, 5, and 10 years of follow-up. Results: Compared with the urologic, polycystic, and other diseases groups, the immunologic group showed significantly lower time of graft survival (9.5 +/- 4 vs 8 +/- 4 vs 8.5 +/- 4 vs 7 +/- 4 years, respectively) and estimated glomerular filtration rate (52.5 +/- 32 vs 49 +/- 22 vs 50 +/- 32 vs 35.5 +/- 30 mL/min; P < .05). Relative risk of 10-year graft loss for the immunologic group was 2.8 (95% confidence interval, 1.6-4.9). Recurrence rate was 12% in the immunologic group versus 1% and 0% in the other diseases and remaining groups (P < .05). The relative risk of 10-year graft loss for patients with recurrence was 2.7 (95% confidence interval, 1.2-6.3). Ten-year graft loss rates for patients with biopsy-proven acute rejection, chronic allograft nephropathy, and recurrent glomerulonephritis were 30%, 23%, and 42% (P < .05). For those with biopsyproven recurrent glomerulonephritis, 10-year estimated glomerular filtration rate was significantly lower than for those with biopsy-proven acute rejection or chronic allograft nephropathy (14 +/- 6 vs 18 +/- 7 vs 30 +/- 10 mL/min; P < .05). Conclusions: Kidney transplant recipients with immunologically mediated kidney diseases have inferior long-term allograft survival and function versus patients with other causes of renal failure. Recurrence represents the strongest risk factor for premature loss of function and transplant failure.
引用
收藏
页码:541 / 545
页数:5
相关论文
共 50 条
  • [1] Long-Term Outcomes and Prognostic Factors in Kidney Transplant Recipients with Polycystic Kidney Disease
    Bhutani, Gauri
    Astor, Brad C.
    Mandelbrot, Didier A.
    Mankowski-Gettle, Lori
    Ziemlewicz, Timothy
    Wells, Shane A.
    Frater-Rubsam, Leah
    Horner, Vanessa
    Boyer, Courtney
    Laffin, Jennifer
    Djamali, Arjang
    KIDNEY360, 2021, 2 (02): : 312 - 324
  • [2] Long-Term Outcomes of Kidney Transplant Recipients With Primary Idiopathic Focal Segmental Glomerulosclerosis
    Staeck, O.
    Halleck, F.
    Budde, K.
    Khadzhynov, D.
    TRANSPLANTATION PROCEEDINGS, 2017, 49 (10) : 2256 - 2259
  • [3] Long-term outcomes in kidney transplant recipients with end-stage kidney disease due to anti-glomerular basement membrane disease
    Singh, Tripti
    Kharadjian, Talar B.
    Astor, Brad C.
    Panzer, Sarah E.
    CLINICAL TRANSPLANTATION, 2021, 35 (02)
  • [4] Urinary Endotrophin and Long-term Outcomes in Kidney Transplant Recipients
    Alkaff, Firas F.
    Kremer, Daan
    Thaunat, Olivier
    Berger, Stefan P.
    van den Born, Jacob
    Genovese, Federica
    Karsdal, Morten A.
    Bakker, Stephan J. L.
    Rasmussen, Daniel G. K.
    Tepel, Martin
    TRANSPLANTATION DIRECT, 2024, 10 (03): : E1591
  • [5] Long-Term Outcomes of Kidney Transplant Recipients With Juvenile Nephronophthisis
    Avci, Begum
    Baskin, Esra
    Gulleroglu, Kaan
    Yilmaz, Aysun Caltik
    Kantar, Asli
    Akdur, Aydincan
    Moray, Gokhan
    Haberal, Mehmet
    EXPERIMENTAL AND CLINICAL TRANSPLANTATION, 2022, 20 (05) : 122 - 125
  • [6] Pretransplant virtual PRA and long-term outcomes of kidney transplant recipients
    Huber, Lu
    Lachmann, Nils
    Niemann, Matthias
    Naik, Marcel
    Liefeldt, Lutz
    Glander, Petra
    Schmidt, Danilo
    Halleck, Fabian
    Waiser, Johannes
    Brakemeier, Susanne
    Neumayer, Hans H.
    Schoenemann, Constanze
    Budde, Klemens
    TRANSPLANT INTERNATIONAL, 2015, 28 (06) : 710 - 719
  • [7] Metabolic Acidosis and Long-Term Clinical Outcomes in Kidney Transplant Recipients
    Park, Seokwoo
    Kang, Eunjeong
    Park, Sehoon
    Kim, Yong Chul
    Han, Seung Seok
    Ha, Jongwon
    Kim, Dong Ki
    Kim, Sejoong
    Park, Su-Kil
    Han, Duck Jong
    Lim, Chun Soo
    Kim, Yon Su
    Lee, Jung Pyo
    Kim, Young Hoon
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2017, 28 (06): : 1886 - 1897
  • [8] Cystatin C and albuminuria as predictors of long-term allograft outcomes in kidney transplant recipients
    Rodrigo, Emilio
    Ruiz, Juan C.
    Fernandez-Fresnedo, Gema
    Fernandez, Maria D.
    Pinera, Celestino
    Palomar, Rosa
    Monfa, Elena
    Gomez-Alamillo, Carlos
    Arias, Manuel
    CLINICAL TRANSPLANTATION, 2013, 27 (02) : E177 - E183
  • [9] Long-term Outcomes of Parathyroidectomy in Kidney Transplant Recipients with Persistent Hyperparathyroidism
    Tseng, Po-Yu
    Yang, Wu-Chang
    Yang, Chih-Yu
    Tarng, Der-Cherng
    KIDNEY & BLOOD PRESSURE RESEARCH, 2015, 40 (04) : 386 - 394
  • [10] Early renal function trajectories, cytomegalovirus serostatus and long-term graft outcomes in kidney transplant recipients
    Law, Jonathan P.
    Borrows, Richard
    McNulty, David
    Sharif, Adnan
    Ferro, Charles J.
    BMC NEPHROLOGY, 2021, 22 (01)